公开(公告)号：US20100321025A1

公开(公告)日：2010-12-23

申请号：US12489684

申请日：2009-06-23

Applicant: Jian Lin ,  Xidong Tang ,  Brian J. Koch ,  Joseph M. Lograsso ,  Andrew J. Namou ,  Rezina S. Nabi ,  Damon R. Frisch

Inventor： Jian Lin ,  Xidong Tang ,  Brian J. Koch ,  Joseph M. Lograsso ,  Andrew J. Namou ,  Rezina S. Nabi ,  Damon R. Frisch

IPC: G01N27/416

CPC classification number: H01M10/4207 ,  H01M10/052 ,  H01M10/441 ,  Y02E60/122

Abstract: A system and method for use with a vehicle battery pack having a number of individual battery cells, such as a lithium-ion battery commonly used in hybrid electric vehicles. In one embodiment, the method evaluates individual battery cells within a vehicle battery pack in order to obtain accurate estimates regarding their average transient voltage effect, open circuit voltage (OCVCell) and/or state of charge (SOCCell) so that a cell balancing process can be performed. These cell evaluations may be performed fairly soon after the vehicle is turned off and in a manner that utilizes a minimal amount of in-vehicle resources.

Abstract translation: 一种用于具有多个单独电池单元的车载电池组的系统和方法，例如通常用于混合电动车辆的锂离子电池。 在一个实施例中，该方法评估车辆电池组中的各个电池单元，以获得关于它们的平均瞬态电压效应，开路电压（OCVCell）和/或充电状态（SOCCell））的准确估计，使得电池平衡过程可以 被执行。 这些电池评估可以在车辆关闭之后很快进行并且以利用最少量车载资源的方式进行。

公开(公告)号：US07855193B2

公开(公告)日：2010-12-21

申请号：US11491766

申请日：2006-07-24

Applicant: Ashis K. Saha ,  Nili Schutz ,  Xiang Yu ,  Dilara McCauley ,  Mercedes Lobera ,  Yael Marantz ,  Jian Lin ,  Srinivasa R. Cheruku ,  Pini Orbach ,  Anurag Sharadendu ,  Robert Christian Penland ,  Kimberley Gannon ,  Sharon Shacham ,  Silvia Noiman ,  Oren Becker

Inventor： Ashis K. Saha ,  Nili Schutz ,  Xiang Yu ,  Dilara McCauley ,  Mercedes Lobera ,  Yael Marantz ,  Jian Lin ,  Srinivasa R. Cheruku ,  Pini Orbach ,  Anurag Sharadendu ,  Robert Christian Penland ,  Kimberley Gannon ,  Sharon Shacham ,  Silvia Noiman ,  Oren Becker

IPC: A61K31/397 ,  A61K31/5377 ,  A61K31/4525 ,  A61K31/4025 ,  A61K31/343 ,  C07D411/06 ,  C07D405/06 ,  C07D205/04 ,  C07D307/80

CPC classification number: C07D405/10 ,  C07D307/80 ,  C07D307/81 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/10 ,  C07D417/14

Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

Abstract translation: 本发明涉及具有作为S1P受体调节剂的活性的通式（I）的化合物，以及这些化合物用于治疗与不适当的S1P受体活性有关的疾病的用途。 这些化合物可用作免疫调节剂，例如用于治疗或预防诸如自身免疫性疾病和相关免疫疾病（包括系统性红斑狼疮），炎症性肠病如克罗恩病和溃疡性结肠炎，I型糖尿病，葡萄膜炎，牛皮癣，重症肌无力，类风湿 关节炎，非肾小球性肾病，肝炎，白塞病，肾小球性肾炎，慢性血小板减少性紫癜，溶血性贫血，肝炎和韦格纳肉芽肿; 并处理其他条件。

公开(公告)号：US07848007B2

公开(公告)日：2010-12-07

申请号：US12167290

申请日：2008-07-03

Applicant: Richard J. Paolini, Jr. ,  David D. Miller ,  Barrett Comiskey ,  Joseph M. Jacobson ,  Bin Wu ,  Charles Howie Honeyman ,  Jian Lin

Inventor： Richard J. Paolini, Jr. ,  David D. Miller ,  Barrett Comiskey ,  Joseph M. Jacobson ,  Bin Wu ,  Charles Howie Honeyman ,  Jian Lin

IPC: G02B26/00 ,  G03G17/04

CPC classification number: G02F1/167

Abstract: A two-phase electrophoretic medium comprises a continuous phase and a discontinuous phase. The discontinuous phase comprises a plurality of droplets, each of which comprises a suspending fluid and at least one particle disposed within the suspending fluid and capable of moving through the fluid upon application of an electric field to the electrophoretic medium. The continuous phase surrounds and encapsulates the discontinuous phase. To reduce the humidity sensitivity of the medium, a non-ionizable or crystalline polymer may be used as the continuous phase.

Abstract translation: 两相电泳介质包括连续相和不连续相。 不连续相包括多个液滴，每个液滴包括悬浮流体和设置在悬浮流体内的至少一个颗粒，并且在向电泳介质施加电场时能够移动通过流体。 连续相围绕并封装不连续相。 为了降低介质的湿度敏感性，可以使用不可离子化或结晶的聚合物作为连续相。

公开(公告)号：US07768233B2

公开(公告)日：2010-08-03

申请号：US11867497

申请日：2007-10-04

Applicant: Jian Lin ,  Xidong Tang ,  Brian J. Koch ,  Damon R. Frisch ,  Michael J. Gielniak

Inventor： Jian Lin ,  Xidong Tang ,  Brian J. Koch ,  Damon R. Frisch ,  Michael J. Gielniak

IPC: H02J7/00

CPC classification number: H01M10/441 ,  G01R31/3651 ,  H01M10/0525 ,  H01M10/443 ,  H01M10/446 ,  H01M10/448 ,  H01M10/482

Abstract: A method for determining the state of charge (SOC) of a lithium ion battery is provided. The method leverages a circuit model of the lithium ion battery, and generates four battery parameters from which the SOC is derived.

Abstract translation: 提供了一种用于确定锂离子电池的充电状态（SOC）的方法。 该方法利用锂离子电池的电路模型，并产生四个电池参数，从其中导出SOC。

公开(公告)号：US20100144698A1

公开(公告)日：2010-06-10

申请号：US12703610

申请日：2010-02-10

Applicant: Thomas Bannister ,  Cassandra Celatka ,  Nizal S. Chandrakumar ,  Hongfeng Deng ,  Zihong Guo ,  Lei Jin ,  Tsveltelina Lazarova ,  Jian Lin ,  Scott T. Moe ,  Pamela Nagafuji ,  Manuel Navia ,  Amy Ripka ,  Michael J. Rynkiewicz ,  Kerry L. Spear ,  James E. Stickler ,  Roger Xie

Inventor： Thomas Bannister ,  Cassandra Celatka ,  Nizal S. Chandrakumar ,  Hongfeng Deng ,  Zihong Guo ,  Lei Jin ,  Tsveltelina Lazarova ,  Jian Lin ,  Scott T. Moe ,  Pamela Nagafuji ,  Manuel Navia ,  Amy Ripka ,  Michael J. Rynkiewicz ,  Kerry L. Spear ,  James E. Stickler ,  Roger Xie

IPC: A61K31/397 ,  C07D205/04 ,  A61P9/00 ,  A61P7/00

CPC classification number: C07D405/06 ,  C07D205/08 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/14

Abstract: Compounds are provided which have the structure Wherein A, B, C, D, m, Y, Ra, Rc, Rd, and Rd′ are as described herein, and which are useful as inhibitors of tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa, and urokinase-type plasminogen activator and may be employed in preventing and/or treating asthma, chronic asthma, allergic rhinitis, and thrombotic disorders.

Abstract translation: 提供具有其中A，B，C，D，m，Y，Ra，Rc，Rd和Rd'如本文所述的结构的化合物，其可用作类胰蛋白酶，凝血酶，胰蛋白酶，因子Xa， 因子VIIa，因子XIa和尿激酶型纤溶酶原激活剂，可用于预防和/或治疗哮喘，慢性哮喘，过敏性鼻炎和血栓形成障碍。

公开(公告)号：US20090322283A1

公开(公告)日：2009-12-31

申请号：US12147539

申请日：2008-06-27

Applicant: Xiaodong Zhang ,  Xidong Tang ,  Jian Lin ,  Yilu Zhang ,  Mutasim A. Salman ,  Yuen-Kwok Chin

Inventor： Xiaodong Zhang ,  Xidong Tang ,  Jian Lin ,  Yilu Zhang ,  Mutasim A. Salman ,  Yuen-Kwok Chin

IPC: H02J7/00

CPC classification number: G01R31/3679 ,  G01R31/3624

Abstract: An embodiment contemplates a method for estimating a capacity of a battery. A state of charge is determined at a first instant of time and at a second instant of time. A difference in the state of charge is determined between the first instant of time and the second instant of time. A net coulomb flow is calculated between the first instant of time and the second instant of time. The battery capacity is determined as a function of the change in the state of charge and the net coulomb flow.

Abstract translation: 实施例考虑了用于估计电池容量的方法。 在第一时刻和第二时刻确定充电状态。 在第一时刻和第二时刻之间确定充电状态的差异。 在第一时刻和第二时刻之间计算净库仑流量。 电池容量被确定为充电状态和净库仑流动的变化的函数。

公开(公告)号：US07501404B2

公开(公告)日：2009-03-10

申请号：US11398438

申请日：2006-04-04

Applicant: Thomas Bannister ,  Cassandra Celatka ,  Nizal S. Chandrakumar ,  Hongfeng Deng ,  Zihong Guo ,  Lei Jin ,  Tsvetelina Lazarova ,  Jian Lin ,  Scott T. Moe ,  Pamela Nagafuji ,  Manuel Navia ,  Amy Ripka ,  Michael J. Rynkiewicz ,  Kerry L. Spear ,  James E. Stickler ,  Roger Xie

Inventor： Thomas Bannister ,  Cassandra Celatka ,  Nizal S. Chandrakumar ,  Hongfeng Deng ,  Zihong Guo ,  Lei Jin ,  Tsvetelina Lazarova ,  Jian Lin ,  Scott T. Moe ,  Pamela Nagafuji ,  Manuel Navia ,  Amy Ripka ,  Michael J. Rynkiewicz ,  Kerry L. Spear ,  James E. Stickler ,  Roger Xie

IPC: C07D205/08 ,  C07D205/085 ,  C07D401/14 ,  C07D401/12 ,  C07D401/06 ,  C07D403/12 ,  C07D403/14 ,  C07D403/04 ,  A61K31/397 ,  A61K31/506 ,  A61K31/4427 ,  A61K31/41

CPC classification number: C07D405/06 ,  C07D205/08 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/14

Abstract: Compounds are provided which have the structure Wherein A, B, C, D, m, Y, Ra, Rc, Rd, and Rd′ are as described herein, and which are useful as inhibitors of tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa, and urokinase-type plasminogen activator and may be employed in preventing and/or treating asthma, chronic asthma, allergic rhinitis, and thrombotic disorders.

Abstract translation: 提供具有其中A，B，C，D，m，Y，Ra，Rc，Rd和Rd'如本文所述的结构的化合物，其可用作类胰蛋白酶，凝血酶，胰蛋白酶，因子Xa， 因子VIIa，因子XIa和尿激酶型纤溶酶原激活剂，可用于预防和/或治疗哮喘，慢性哮喘，过敏性鼻炎和血栓形成障碍。

公开(公告)号：US20080173081A1

公开(公告)日：2008-07-24

申请号：US11625834

申请日：2007-01-23

Applicant: Jian Lin ,  Yong Xu ,  Wenbo Wang ,  Michael R. Grimes

Inventor： Jian Lin ,  Yong Xu ,  Wenbo Wang ,  Michael R. Grimes

IPC: G01M17/00

CPC classification number: B60W40/06

Abstract: A rough road detection system includes an engine speed module, a feature space module, a normalization module, and a rough road module. The engine speed module generates an engine speed signal based on a crank signal. The feature space module generates a feature space signal based on the engine speed signal. The normalization module generates a normalized signal. The normalized signal is based on the feature space signal and a normalization value that varies in accordance with the engine speed signal. The rough road module determines whether a rough road condition exists based on the normalized signal.

Abstract translation: 粗糙的道路检测系统包括发动机转速模块，特征空间模块，归一化模块和粗糙的道路模块。 发动机转速模块基于曲柄信号产生发动机转速信号。 特征空间模块基于发动机速度信号产生特征空间信号。 归一化模块生成归一化信号。 归一化信号基于特征空间信号和根据发动机速度信号而变化的归一化值。 粗糙道路模块基于归一化信号来确定是否存在粗暴的道路状况。

公开(公告)号：US20080064677A9

公开(公告)日：2008-03-13

申请号：US11491766

申请日：2006-07-24

Applicant: Ashis K. Saha ,  Nili Schutz ,  Anurag Sharadendu ,  Dilara McCauley ,  Mercedes Lobera ,  Yael Marantz ,  Jian Lin ,  Srinivasa Rao Cheruku ,  Pini Orbach ,  Anurag Sharadendu ,  Robert Christian Penland ,  Kimberley Gannon ,  Sharon Shacham ,  Silvia Noiman ,  Oren Becker

Inventor： Ashis K. Saha ,  Nili Schutz ,  Anurag Sharadendu ,  Dilara McCauley ,  Mercedes Lobera ,  Yael Marantz ,  Jian Lin ,  Srinivasa Rao Cheruku ,  Pini Orbach ,  Anurag Sharadendu ,  Robert Christian Penland ,  Kimberley Gannon ,  Sharon Shacham ,  Silvia Noiman ,  Oren Becker

IPC: A61K31/452 ,  A61K31/397 ,  C07D405/02

CPC classification number: C07D405/10 ,  C07D307/80 ,  C07D307/81 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/10 ,  C07D417/14

Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

Abstract translation: 本发明涉及具有作为S1P受体调节剂的活性的通式（I）的化合物，以及这些化合物用于治疗与不适当的S1P受体活性有关的疾病的用途。 这些化合物可用作免疫调节剂，例如用于治疗或预防诸如自身免疫性疾病和相关免疫疾病（包括系统性红斑狼疮），炎症性肠病如克罗恩病和溃疡性结肠炎，I型糖尿病，葡萄膜炎，牛皮癣，重症肌无力，类风湿 关节炎，非肾小球性肾病，肝炎，贝切特氏病，肾小球性肾炎，慢性血小板减少性紫癜，溶血性贫血，肝炎和韦格纳肉芽肿; 并处理其他条件。

公开(公告)号：US20070173487A1

公开(公告)日：2007-07-26

申请号：US11491766

申请日：2006-07-24

Applicant: Ashis K. Saha ,  Nili Schutz ,  Anurag Sharadendu ,  Dilara McCauley ,  Mercedes Lobera ,  Yael Marantz ,  Jian Lin ,  Srinivasa Rao Cheruku ,  Pini Orbach ,  Anurag Sharadendu ,  Robert Christian Penland ,  Kimberley Gannon ,  Sharon Shacham ,  Silvia Noiman ,  Oren Becker

Inventor： Ashis K. Saha ,  Nili Schutz ,  Anurag Sharadendu ,  Dilara McCauley ,  Mercedes Lobera ,  Yael Marantz ,  Jian Lin ,  Srinivasa Rao Cheruku ,  Pini Orbach ,  Anurag Sharadendu ,  Robert Christian Penland ,  Kimberley Gannon ,  Sharon Shacham ,  Silvia Noiman ,  Oren Becker

IPC: A61K31/452 ,  A61K31/397 ,  C07D405/02

CPC classification number: C07D405/10 ,  C07D307/80 ,  C07D307/81 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/10 ,  C07D417/14

Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

Abstract translation: 本发明涉及具有作为S1P受体调节剂的活性的通式（I）的化合物，以及这些化合物用于治疗与不适当的S1P受体活性有关的疾病的用途。 这些化合物可用作免疫调节剂，例如用于治疗或预防诸如自身免疫性疾病和相关免疫疾病（包括系统性红斑狼疮），炎症性肠病如克罗恩病和溃疡性结肠炎，I型糖尿病，葡萄膜炎，牛皮癣，重症肌无力，类风湿 关节炎，非肾小球性肾病，肝炎，贝切特氏病，肾小球性肾炎，慢性血小板减少性紫癜，溶血性贫血，肝炎和韦格纳肉芽肿; 并处理其他条件。